Group 1 - The company will hold its third extraordinary general meeting of shareholders in 2025 on November 26, 2025 [3][36] - The meeting will be convened by the company's board of directors and will comply with relevant laws and regulations [2][4] - Shareholders registered by the close of business on November 19, 2025, will have the right to attend the meeting [5][6] Group 2 - The company plans to appoint a new auditing firm, Deloitte Touche Tohmatsu Certified Public Accountants LLP, for the 2025 fiscal year [18][20] - The reason for the change is that the previous auditing firm, Rongcheng Certified Public Accountants LLP, has reached the maximum service duration as per regulatory guidelines [19][27] - The proposed audit fees for the new firm are set at 1.885 million yuan, which includes 1.585 million yuan for financial audit and 300,000 yuan for internal control audit, reflecting a 5.75% decrease from the previous period [20][26]

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2025-072 九芝堂股份有限公司 1、拟聘任的会计师事务所：致同会计师事务所（特殊普通合伙）（以下简 称"致同所"） 2、原聘任的会计师事务所：容诚会计师事务所（特殊普通合伙）（以下简 称"容诚所"） 3、变更会计师事务所的原因：在执行完九芝堂股份有限公司（以下简称"公 司"）2024 年度审计工作后，容诚所为公司提供审计服务已达到中华人民共和 国财政部（以下简称"财政部"）、国务院国有资产监督管理委员会（以下简 称"国资委"）及中国证券监督管理委员会（以下简称"证监会"）联合印发 的《国有企业、上市公司选聘会计师事务所管理办法》（财会[2023]4 号）（以 下简称"《管理办法》"）规定的最长年限，根据《管理办法》对会计师事务 所轮换的相关规定，公司 2025 年度需变更会计师事务所，经公开招标和审慎决 策，拟聘任致同会计师事务所（特殊普通合伙）为公司 2025 年度财务审计及内 控审计机构。 公司已就本次选聘会计师事务所的相关事宜与容诚所、致同所进行了充分 沟通，前任会计师事务所已明确知悉该事项并确认无异议。 容诚所在为公司提供审计服务期间 ...

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2025-071 九芝堂股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：九芝堂股份有限公司董事会 3、会议召开的合法、合规性： 本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股 票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规 定。 4、会议时间： 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 11 月 19 日 7、出席对象： （1）凡在股权登记日 15:00 收市时在中国证券登记结算有限责任公司深圳 分公司登记在册的公司全体股东均有权出席股东会，并可以以书面形式委托代理 人出席会议和参加表决，该股东代理人不必是本公司股东； （2）本公司董事、高级管理人员； （3）本公司聘请的律师； 九芝堂股份有限 ...

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2025-070 九芝堂股份有限公司 第九届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 一、董事会会议召开情况 表决情况：同意 9 票，反对 0 票，弃权 0 票，审议通过。 2、关于召开公司 2025 年第三次临时股东会的议案 公司定于 2025 年 11 月 26 日召开公司 2025 年第三次临时股东会。详细内容 请参看公告在《中国证券报》《证券时报》《证券日报》《上海证券报》及巨潮资 讯网的《九芝堂股份有限公司关于召开 2025 年第三次临时股东会的通知》（公告 九芝堂股份有限公司 1 九芝堂股份有限公司第九届董事会第十二次会议通知于 2025 年 11 月 3 日以 电子邮件方式发出，会议于 2025 年 11 月 6 日以通讯方式召开。会议应出席董事 9 名，实际出席董事 9 名。本次董事会会议的召开符合有关法律、行政法规、部 门规章、规范性文件和公司章程的规定。 二、董事会会议审议情况 在公司董事充分理解会议议案并表达意见后，本次会议一致审议通过了以下 ...

Core Insights - The 25th CeMAT ASIA exhibition in Shanghai showcased over 900 exhibitors and introduced the concept of "embodied logistics" solutions for the first time globally [1] Group 1: Technology and Innovation - The collaboration between ROBOTERA and Beizhi Technology demonstrated a humanoid robot, "Xingdong L7," capable of performing a full range of intelligent operations in pharmaceutical warehousing, including sorting, scanning, and supplying [4] - The core of this operation is the self-developed end-to-end VLA embodied model ERA-42, which enables real-time closed-loop processes for visual recognition, action planning, and task execution, showcasing strong adaptability to dynamic environments [4][5] - The ERA-42 model is one of only four globally that supports precise control of a five-finger dexterous hand, providing significant operational capabilities in complex logistics scenarios [5] Group 2: Performance and Flexibility - The Xingdong L7 robot features a high-performance bionic 7-axis robotic arm and a unique fully direct-drive dexterous hand, allowing for efficient and flexible operations in various logistics tasks [5] - The integration of diverse data sources enables the robot to train effectively and adapt to various operational challenges, enhancing its ability to handle different shapes and designs of pharmaceutical packaging [6] - The embodied intelligence solution addresses the limitations of traditional automation, which often relies on fixed tracks and preset programs, by offering a flexible approach that can quickly adapt to changing SKU requirements [7] Group 3: Market Potential and Applications - The flexibility of the Xingdong L7 allows for rapid learning of new material characteristics, significantly reducing adaptation time compared to traditional automated sorting equipment [7] - This technology has the potential to expand into various industries, including e-commerce, pharmaceuticals, automotive parts, and retail, paving the way for a transition from "point automation" to "full-process intelligence" in logistics [7]

Core Viewpoint - The company, Jiuzhitang, has reported a significant decline in net profit attributable to shareholders, primarily due to a decrease in operating income and an increase in expense ratios, while also announcing a strategic investment in Harbin Jixianglong Biotechnology Co., Ltd. to enhance its business layout in the pharmaceutical industry [3][11][15]. Financial Performance - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 118.77% compared to the same period last year, attributed to a decline in operating income, increased expense ratios, and reduced investment income [3]. - The net cash flow from operating activities increased by 527.78% year-to-date compared to the same period last year, mainly due to improved collection efforts and reduced cash payments for goods and services [3]. Investment Overview - Jiuzhitang signed an investment agreement to acquire a 51.6667% stake in Harbin Jixianglong Biotechnology Co., Ltd. for a total consideration of RMB 31 million, which includes RMB 21 million for existing shares and RMB 10 million for new capital [11][15][55]. - The investment aims to enhance Jiuzhitang's capabilities in drug production, research and development, and related industries, thereby improving its overall competitive strength [15]. Company Background - Harbin Jixianglong is a national high-tech enterprise specializing in the research, production, and technical services of peptide drugs, with over ten years of experience in the peptide industry [24][25]. - The company has developed a strong competitive advantage through its proprietary technologies and has received multiple production approvals for its peptide raw materials [28][32]. Financial Valuation - The valuation of Harbin Jixianglong was assessed using both the income approach and market approach, with the income approach yielding a valuation of RMB 54.81 million, reflecting a significant increase from its book value [49][50]. - The agreed transaction price for the equity transfer was based on this valuation, with the total consideration set at RMB 31 million [55].

Core Insights - JiuZhiTang has acquired a 51.6667% stake in Harbin JiXiangLong Biotechnology Co., Ltd. for RMB 2.1 billion and invested an additional RMB 1 billion, allowing JiXiangLong to be included in JiuZhiTang's consolidated financial statements [1][2] - JiXiangLong specializes in the research, production, and technical services of peptide-based generic drugs and innovative drugs, holding 10 production approvals for raw materials and 1 for formulations, with 8 products entering national procurement [1][2] - The acquisition enables JiuZhiTang to enter the peptide raw material drug sector, enhancing its product range and industrial chain layout [1][2] Company Overview - JiXiangLong is recognized as a national high-tech enterprise with a strong technical team and a comprehensive technology system in the peptide drug field, indicating significant growth potential and investment value [2] - JiuZhiTang is a pharmaceutical company that integrates research, production, sales, and health management, focusing on traditional and modern Chinese medicine, biopharmaceuticals, and health products [2] - The integration is expected to create synergies in production, sales channels, research, and technology, enhancing JiuZhiTang's competitiveness in the pharmaceutical sector [2] Market Implications - The deep integration of JiuZhiTang and JiXiangLong is anticipated to improve the company's risk resilience, profitability, and growth potential, with ongoing market attention on the integration effects and synergy value [2]

Core Insights - The core viewpoint of the article highlights the significant decline in both revenue and net profit for Jiuzhitang in the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 1.627 billion, representing a year-on-year decrease of 21.13% [1] - The net profit attributable to the parent company was 152 million, reflecting a year-on-year decline of 36.94% [1] Contributing Factors - Jiuzhitang attributed the decline in net profit to a decrease in operating revenue, an increase in expense ratio, and reduced investment income during the third quarter [1]

Core Viewpoint - The company Jiuzhitang (000989) plans to acquire a controlling stake in Harbin Jixianglong Biotechnology Co., Ltd. for a total of 2.1 billion yuan, which will enhance its product offerings and improve its financial performance [1] Group 1: Transaction Details - Jiuzhitang will acquire 35% of Jixianglong's existing shares from current shareholders for 2.1 million yuan and will subscribe to an additional 16.67% of new registered capital for 1 billion yuan [1] - After the completion of the transaction, Jiuzhitang will hold a total of 51.67% of Jixianglong, which will become a subsidiary included in Jiuzhitang's consolidated financial statements [1] Group 2: Company Profile - Jixianglong is a national high-tech enterprise specializing in the research, production, and technical services of peptide generic drugs and innovative drug formulations [1] Group 3: Strategic Implications - The acquisition is expected to enrich Jiuzhitang's product categories and improve its industry chain layout, thereby expanding its business scale and enhancing profitability [1] - The consolidation of Jixianglong's financials is anticipated to increase Jiuzhitang's revenue and profit levels, improving its risk resistance and sustainable profitability [1]

Core Insights - JiuZhiTang announced the acquisition of a 51.6667% stake in Harbin JiXiangLong Biotechnology Co., Ltd. for 210 million yuan and an additional investment of 100 million yuan, which will allow JiXiangLong to be included in JiuZhiTang's consolidated financial statements [1][2] - JiXiangLong specializes in the research, production, and technical services of peptide generic drugs and has obtained multiple production approvals, ranking third in China for peptide raw material drug approvals [1][2] Group 1 - The acquisition will enable JiuZhiTang to quickly enter the peptide raw material drug sector, enhancing its product structure and industrial chain layout [1] - JiXiangLong has received 10 production approvals for raw materials and 1 for formulations, with 8 products already included in national procurement [1] - The company has completed DMF filings for Semaglutide and Teriparatide with the FDA, allowing sales in U.S. pharmacies [1] Group 2 - The integration of JiXiangLong is expected to create synergies in production, sales channels, research, and technology, establishing new growth points for JiuZhiTang [2] - JiXiangLong will benefit from JiuZhiTang's management, platform, funding, brand, and channel support, accelerating its development [2] - Market analysts believe that this deep integration will enhance JiuZhiTang's risk resistance, sustainable profitability, and future growth potential [2]